



RECEIVED
MAY 8 8 2002
PATENT
TECH CENTER 1000/2000
Docket No. 265.0019201

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): High et al.) Group Art Unit: 1614
Serial No.: 09/877,220) Examiner: Unknown
Confirmation No.: 8535)
Filed: 8 June 2001)
For: METHODS FOR TREATING NEUROPATHOLOGICAL STATES AND
NEUROGENIC INFLAMMATORY STATES AND METHODS FOR
IDENTIFYING COMPOUNDS USEFUL THEREIN

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202

Sir:

Prior to taking up the above-identified application for examination, please amend the application as follows:

In the Specification

Please replace the paragraph beginning at page 10, line 5, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

Cells useful in the present invention have a glutamate receptor, preferably an NMDA glutamate receptor, on the cell surface. Examples of such cells include, for instance, neurons. Examples of useful neurons that can be used *ex vivo* include cultured neuroblastoma cells, preferably rat, mouse, or human, more preferably human. An example of a cultured human neuroblastoma cell is SHSY5Y (ATCC CRL-2266). Other examples of useful *ex vivo* neurons include neurons isolated from the dorsal horn of the spinal cord, dorsal root ganglia and other cell bodies of peripheral nerves, hippocampal or other limbic or cortical neurons. Preferably the neurons are removed from a rat. Examples of *in vivo*